| Detailed information |
|---|
| CancerLivER ID | 2247 |
| Biomarker | B2M |
| Biomarker Name/Symbol (given in Publication) | beta-2-microglobulin or B2M |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Differentially expressed gene |
| Experimental Condition | HCC and CHC v/s normal |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upregulated in HCC and CHC v/s normal (with 67 fold change) |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 11401510 |
| Type of Biomarker | Diagnostic |
| Pathway | Immune associated pathways: antigen presentation and processing |
| Cohort | Training dataset: Samples separately obtained from the tumor (diagnosed as well differentiated HCC) and noncancerous liver (diagnosed as chronic active hepatitis); Validation Dataset: 4 HCC tissues from 4 patients, noncancerous background liver tissues from the same patients, and 3 unrelated normal |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC and CHC (Chronic hepatitis C) |
| Year of Publication | 2001 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |